{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-314745","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.098470+00:00","generated_at":"2026-06-20T21:52:43.710775+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tempest Therapeutics Amends Loan Agreement with Oxford Finance, Adds Borrowers and Extends Interest-Only Period","bullets":["Tempest Therapeutics entered into a First Amendment to Loan and Security Agreement with Oxford Finance LLC on Dec 23, 2022.","The amendment adds Tempest Therapeutics and Millendo Therapeutics US as co-borrowers under the loan.","Interest-only repayment period extended through Dec 31, 2023, with possible extension to June 30, 2024.","Lender permitted a one-time prepayment of $5.0 million by Dec 28, 2022.","Minimum liquidity covenant of $5.0 million in collateral accounts required."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-314745","json":"https://secwatch.observer/filing/0001193125-22-314745.json","markdown":"https://secwatch.observer/filing/0001193125-22-314745.md","text":"https://secwatch.observer/filing/0001193125-22-314745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/0001193125-22-314745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/d411465d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:52:43.710775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc3d2a1a117526f743af329d0c965f50a0008065","claim":"Tempest Therapeutics, Inc. amended First Amendment to Loan and Security Agreement with Oxford Finance LLC, as collateral agent, and certain additional lenders valued at $5.0 million (effective 2022-12-23).","evidence_excerpt":"On December 23, 2022, Tempest Therapeutics, Inc. (the “ Company ”) entered into a First Amendment to Loan and Security Agreement (the “ LSA Amendment ”), which modified that certain Loan and Security Agreement dated as of January 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “ Loan Agreement ”) by and among TempestTX, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ TempestTX ”), Oxford Finance LLC (the “ Lender ”), as collateral agent, and certain additional lenders party thereto from time to time. Pursuant to the LSA Amendment, (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Millendo ”), were joined as co-borrowers under the Loan Agreement, (ii) the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances), and (iii) a sec","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312522314745/0001193125-22-314745-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC, as collateral agent, and certain additional lenders"},{"label":"Value","value":"$5.0 million"},{"label":"Effective","value":"2022-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}